Log in

Relevant bibliographies by topics / Inhaled glucocorticosteroids

Contents

Journal articles
Books
Book chapters
Conference papers

Academic literature on the topic 'Inhaled glucocorticosteroids'

Author: Grafiati

Published: 4 June 2025

Last updated: 23 June 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Inhaled glucocorticosteroids.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Inhaled glucocorticosteroids"

1

Pedersen, S. "Comparing inhaled glucocorticosteroids." Allergy 54, s49 (1999): 42–50. http://dx.doi.org/10.1111/j.1398-9995.1999.tb04387.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Yates, D. H., M. Worsdell, and P. J. Barnes. "Effect of an inhaled glucocorticosteroid on mast cell and smooth muscle beta 2 adrenergic tolerance in mild asthma." Thorax 53, no. 2 (1998): 110–13. http://dx.doi.org/10.1136/thx.53.2.110.

Full text

Abstract:

BACKGROUND: Regular inhaled beta 2 agonist therapy is associated with loss of bronchoprotection to indirect bronchial provocation challenges such as allergen or adenosine monophosphate (AMP), while directly acting challenge is less affected, implying preferential mast cell tolerance. Glucocorticosteroids may reverse such beta 2 adrenoreceptor tolerance and upregulate mast cell beta 2 adrenoceptor function. METHODS: The effect of single high dose glucocorticosteroids on terbutaline induced loss of bronchoprotection was studied in a placebo controlled, double blind, cross-over study. Fifteen asthmatic subjects who were not taking inhaled glucocorticosteroids underwent two 10-day treatment periods with terbutaline (500 micrograms four times daily via Turbohaler), each followed by a single dose of inhaled budesonide (800 micrograms via Turbohaler) or identical placebo. RESULTS: Regular treatment with terbutaline resulted in significant loss of bronchoprotection to AMP (mean difference (95% CI) -1.7 (-3.0 to 0.4) doubling dilutions) but not to methacholine (mean difference -0.1 (-1.0 to 0.8) doubling dilutions). Single high dose budesonide increased the protective effect of terbutaline more to AMP than to methacholine challenge (+0.76 (0.3) doubling dilutions compared with +0.13 (0.4) doubling dilutions, respectively). The mean (SE) difference between budesonide and placebo for methacholine challenge was 0.08 (0.14) whereas that for AMP was 0.075 (0.15); p = NS. The difference in PC20 was not statistically significant when compared with placebo for either challenge agent. CONCLUSIONS: Inhaled glucocorticosteroids in a single dose had no significant effect in restoring terbutaline induced loss of bronchoprotection, implying that mast cell beta 2 adrenoceptor sensitivity is not restored by a single dose of an inhaled glucocorticosteroid in asthma.

APA, Harvard, Vancouver, ISO, and other styles

3

Garashchenko, T. I., and G. D. Tarasova. "Inhaled glucocorticosteroids in otorhinolaryngology." Meditsinskiy sovet = Medical Council, no. 1 (March 9, 2020): 50–58. http://dx.doi.org/10.21518/2079-701x-2020-1-50-58.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Gauvreau, Gail M., Mark D. Inman, Margaret Kelly, Richard M. Watson, Sandra C. Dorman, and Paul M. O’Byrne. "Increased Levels of Airway Neutrophils Reduces the Inhibitory Effects of Inhaled Glucocorticosteroids on Allergen-Induced Airway Eosinophils." Canadian Respiratory Journal 9, no. 1 (2002): 26–32. http://dx.doi.org/10.1155/2002/161969.

Full text

Abstract:

BACKGROUND: Treatment with inhaled glucocorticosteroids attenuates allergen-induced airway inflammation but is less effective in people with asthma who have noneosinophilic airway inflammation.OBJECTIVE: Studies in which glucocorticosteroid treatment was used before allergen challenges were re-examined to determine whether the efficacy of steroid treatment could be predicted by baseline levels of sputum inflammatory cells.PATIENTS AND METHODS: Twenty-eight nonsmoking subjects with atopic asthma controlled by beta2-agonists participated in only one of three studies, each carried out with a double-blind, placebo controlled, randomized, crossover design. Subjects were treated with glucocorticosteroids or placebo for six to eight days and then underwent allergen inhalation challenge. Spirometry was measured for 7 h after allergen challenge, and then sputum inflammatory cells were measured. Sputum inflammatory cells were also measured before and after treatment, and 24 h after allergen challenge. The per cent inhibition of the allergen-induced airway responses by glucocorticosteroids was calculated.RESULTS: Inhaled gluticocorticosteroids significantly attenuated the early and late asthmatic responses, and the number of allergen-induced sputum eosinophils (P<0.05). There was a significant negative relationship between the number of sputum neutrophils at baseline, and the per cent inhibition of allergen-induced sputum eosinophils measured at 7 h (r=-0.61, P<0.001) and 24 h (r=-0.73, P<0.0001) after challenge, suggesting that glucocorticosteroids are less effective in attenuating allergen-induced airway inflammation in subjects with high levels of neutrophils. There was no correlation between the number of sputum eosinophils at baseline and the per cent inhibition of allergen-induced responses.CONCLUSIONS: Baseline airway neutrophils, not eosinophils, can be used to predict the efficacy of inhaled steroids on allergen-induced sputum eosinophils.

APA, Harvard, Vancouver, ISO, and other styles

5

Hughes, J. R., E. M. Higgins, and A. W. du Vivier. "Acne associated with inhaled glucocorticosteroids." BMJ 305, no. 6860 (1992): 1000. http://dx.doi.org/10.1136/bmj.305.6860.1000.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Ignatova, G. I., V. N. Antonov, and I. A. Zakharova. "Clinical case of indacaterol / glycopyrronium bromide prescription in a patient with severe copd and concomitant pathology." Meditsinskiy sovet = Medical Council, no. 9 (June 5, 2024): 27–30. http://dx.doi.org/10.21518/ms2024-207.

Full text

Abstract:

Combinations of inhaled glucocorticosteroids (IHGC) and long-acting bronchodilator inhalers (LABA inhalers) have been widely used to treat chronic obstructive pulmonary disease (COPD) over the past two decades. Prescription of these drugs was based on large studies showing that this therapeutic regimen was more effective compared to placebo and monotherapy. The article presents a clinical case report of a patient with severe course of COPD and coronary heart disease (CHD). Up-to-date concepts of using dual bronchodilator therapy when switching from combinations of inhaled glucocorticosteroids and long-acting bronchodilator inhalers (IHGC/LABA) is discussed. A patient with COPD and coronary artery disease, atrial fibrillation while using IHGC/LABA had progressive respiratory failure, frequent exacerbations, and acute symptomatology. As there is evidence that the use of IHGC/LABA has a number of limitations in the combined course of COPD and cardiovascular diseases, first of all in coronary artery disease and arrhythmias, it was recommended to replace therapy with a combination of dual bronchodilators – a long-acting muscarinic antagonist (LAMA) and a long-acting β agonist (LABA). The therapy resulted in stabilization of the condition, reduction of clinical symptoms, and absence of cardiovascular complications. It has been concluded that the dual bronchodilator therapy with a combination of glycopyrronium bromide and indacaterol is prioritized in COPD, including COPD combined with cardiovascular pathology; no increase in cardiovascular events in patients with COPD combined with coronary artery disease is observed; Breezhaler inhaler is user-friendly for the patients and has advantages over other delivery devices.

APA, Harvard, Vancouver, ISO, and other styles

7

Czerwińska Pawluk, Iwona, Elwira Paula Pawluk, Angelo Daniel Szymaszek, and Walery Zukow. "Concerns of patients with bronchial asthma against the use of inhaled glucocorticosteroids." Journal of Education, Health and Sport 13, no. 2 (2023): 280–86. http://dx.doi.org/10.12775/jehs.2023.13.02.040.

Full text

Abstract:

The medical literature describes the problem of anxiety and fear of using glucocorticosteroid drugs and their side effects in patients with bronchial asthma. Frequently, unjustified fears of patients are the cause of non-compliance with therapeutic recommendations, which in turn results in the lack of therapeutic effects [24]. In order to counteract this unfavorable phenomenon, to increase the safety and effectiveness of therapy in patients with bronchial asthma, large-scale educational activities should be carried out both among medical staff and patients on the importance of glucocorticosteroids in the treatment of bronchial asthma and their impact on the degree of control of the disease.

APA, Harvard, Vancouver, ISO, and other styles

8

Mendes, E. S., A. Pereira, I. Danta, R. C. Duncan, and A. Wanner. "Comparative bronchial vasoconstrictive efficacy of inhaled glucocorticosteroids." European Respiratory Journal 21, no. 6 (2003): 989–93. http://dx.doi.org/10.1183/09031936.03.00072402.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Pauwels, Romain. "Inhaled Glucocorticosteroids and Chronic Obstructive Pulmonary Disease." American Journal of Respiratory and Critical Care Medicine 165, no. 12 (2002): 1579–80. http://dx.doi.org/10.1164/rccm.2204029.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Holley, Lauren. "Novel developments in equine asthma." UK-Vet Equine 8, no. 1 (2024): 6–12. http://dx.doi.org/10.12968/ukve.2024.8.1.6.

Full text

Abstract:

Equine asthma is a disease which affects horses across the globe and can range from mild exercise impairment to severe debilitation that decreases the horse's quality of life. Treatment currently focuses on environmental management, bronchodilators and systemic and inhaled glucocorticosteroids. Glucocorticosteroids remain the mainstay of therapy but can have deleterious side effects; therefore, there is a critical need for the development of new therapies. Nebulised lidocaine and immunomodulatory therapy both hold promise for the treatment of equine asthma, especially with respect to avoiding the deleterious effects of glucocorticosteroids.

APA, Harvard, Vancouver, ISO, and other styles

More sources

Books on the topic "Inhaled glucocorticosteroids"

1

Jennings, Barbara H. Assessment of systemic effects of inhaled glucocorticosteroids. Univ., 1990.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Inhaled glucocorticosteroids"

1

"The Role of Direct Assessment of Airway Inﬂammation in Evaluating Inhaled Glucocorticosteroid Efﬁcacy and in Managing the Asthmatic Patient." In Inhaled Steroids in Asthma. CRC Press, 2001. http://dx.doi.org/10.3109/9780203908532-19.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Inhaled glucocorticosteroids"

1

Titova, Olga, Natalya Kuzubova, and Elena Lebedeva. "Protective effect of inhaled glucocorticosteroids on COPD model." In ERS International Congress 2020 abstracts. European Respiratory Society, 2020. http://dx.doi.org/10.1183/13993003.congress-2020.567.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Khodosh, Eduard, Peter Poteiko, Valeriy Krutko, and Dmitriy Khoroshun. "Influence of inhaled glucocorticosteroids on course of the bronchiectasis." In Annual Congress 2015. European Respiratory Society, 2015. http://dx.doi.org/10.1183/13993003.congress-2015.pa2963.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Mendes, Eliana, Adam Wanner, Meela Parker, Andreas Schmid, Johana Arana, and Barry Hurwitz. "Inhaled glucocorticosteroid treatment effects on pulmonary artery pressure and cardiac function in healthy smokers." In ERS International Congress 2016 abstracts. European Respiratory Society, 2016. http://dx.doi.org/10.1183/13993003.congress-2016.pa1880.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Mendes, Eliana S., Jose Eduardo D. Cancado, Patricia Rebolledo, et al. "Airway And Extrapulmonary Vascular Endothelial Function In Healthy Smokers: Effect Of An Inhaled Glucocorticosteroid." In American Thoracic Society 2011 International Conference, May 13-18, 2011 • Denver Colorado. American Thoracic Society, 2011. http://dx.doi.org/10.1164/ajrccm-conference.2011.183.1_meetingabstracts.a3625.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Titova, Olga, Natalya Kuzubova, Elena Lebedeva, and Elizaveta Volchkova. "Protective effect of inhaled glucocorticosteroid and long-acting beta2-agonist combination on COPD model." In ERS International Congress 2021 abstracts. European Respiratory Society, 2021. http://dx.doi.org/10.1183/13993003.congress-2021.pa735.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!